# LXEO catalysts: Lexeo Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/lxeo/catalysts

> Lexeo Therapeutics, Inc. (LXEO) has 3 upcoming catalysts. The next is the Lexeo Therapeutics, Inc. topline data readout, 2H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for LXEO?

Lexeo Therapeutics, Inc. (LXEO) has 3 upcoming catalysts. The next is the Lexeo Therapeutics, Inc. topline data readout, 2H 2027. Press release filed with the SEC (EX-99): "Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027" [Calendar and source filings](https://sec-api.dev/companies/lxeo/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-345722, https://www.sec.gov/Archives/edgar/data/1907108/000119312526345722/lxeo-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-08-12. Cite: https://sec-api.dev/companies/lxeo/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Lexeo Therapeutics, Inc. |
| Ticker | LXEO (Nasdaq) |
| SEC CIK | 1907108 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/lxeo |

## Cash runway

Cash $234.2M as of 2026-06-30; quarterly burn $17.6M; about 39.9 months of runway at that rate (XBRL company facts, accession 0001193125-26-345724).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Apr 2024 | [Cardiomyopathy trial start](https://sec-api.dev/pdufa/cardiomyopathy) | LXEO | FA cardiomyopathy | completed | "We entered into a third license agreement with Cornell University, or Third Cornell License Agreement, in April 2024 pursuant to which we obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate AAVrh10.hFXN, known as LX2006 at Lexeo." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1907108/000119312526345724/lxeo-20260630.htm)) |
| November 11, 2024 | [Lexeo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lxeo/catalysts) | LXEO |  | completed | "Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000095017024125940/lxeo-ex99_1.htm)) |
| Mar 2025 | [Lexeo Therapeutics, Inc. interim data readout](https://sec-api.dev/companies/lxeo/catalysts) | LXEO |  | completed, positive | "LX2020 for the Treatment of PKP2-ACM: In March 2025, Lexeo shared positive interim data of LX2020 from the low-dose cohort in the HEROIC-PKP2 Phase 1/2 clinical trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000095017025068534/lxeo-ex99_1.htm)) |
| March 24, 2025 | [Lexeo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lxeo/catalysts) | LXEO |  | completed | "Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000095017025043485/lxeo-ex99_1.htm)) |
| Q2 2025 | [LX1001 interim data readout](https://sec-api.dev/pdufa/lx1001) | LXEO |  | scheduled | "Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial; initial clinical data including safety and biodistribution on track for late Q1 / early Q2 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000095017024125940/lxeo-ex99_1.htm)) |
| April 7, 2025 | [Cardiomyopathy interim data readout](https://sec-api.dev/pdufa/cardiomyopathy) | LXEO |  | completed, positive | "NEW YORK - April 7, 2025 (GLOBE NEWSWIRE) - Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced positive interim data across all dose cohorts of LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000095017025051345/lxeo-ex99_2.htm)) |
| May 12, 2025 | [Lexeo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lxeo/catalysts) | LXEO |  | completed | "Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000095017025068534/lxeo-ex99_1.htm)) |
| August 14, 2025 | [Lexeo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lxeo/catalysts) | LXEO |  | completed | "Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000095017025108426/lxeo-ex99_1.htm)) |
| Nov 2025 | [HEK293 FDA approval](https://sec-api.dev/pdufa/hek293) | LXEO |  | completed, approved | "In November 2025, FDA approved the analytical comparability report establishing comparability between LX2006 HEK293 and Sf9 manufacturing processes, endorsing use of the optimized, Sf9 final commercial manufacturing process for LX2006 in the planned pivotal study and clearing comparability requirements to begin dosing patients." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000119312526131792/lxeo-ex99_1.htm)) |
| November 5, 2025 | [Lexeo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lxeo/catalysts) | LXEO |  | completed | "Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000119312525265755/lxeo-ex99_1.htm)) |
| Jan 2026 | [HEK293 interim data readout](https://sec-api.dev/pdufa/hek293) | LXEO |  | scheduled | "Completed enrollment of LX2020 HEROIC-PKP2 Phase I/II trial with ten participants dosed; interim data from low-dose cohort reported and additional clinical data from high-dose cohorts on track for January 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000119312525265755/lxeo-ex99_1.htm)) |
| Jan 2026 | [Cardiomyopathy interim data readout](https://sec-api.dev/pdufa/cardiomyopathy) | LXEO |  | completed, positive | "In January 2026, we announced positive interim data from the HEROIC Phase 1/2 clinical trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm)) |
| 1H 2026 | [HEK293 trial start](https://sec-api.dev/pdufa/hek293) | LXEO |  | scheduled | "Next Steps: Lexeo plans to initiate a registrational study in the first half of 2026, pending finalization of the trial protocol in early 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000119312525265755/lxeo-ex99_1.htm)) |
| March 30, 2026 | [Lexeo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lxeo/catalysts) | LXEO |  | completed | "Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000119312526131792/lxeo-ex99_1.htm)) |
| May 11, 2026 | [Lexeo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lxeo/catalysts) | LXEO |  | completed | "Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000119312526215674/lxeo-ex99_1.htm)) |
| August 12, 2026 | [Lexeo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lxeo/catalysts) | LXEO |  | completed | "Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000119312526345722/lxeo-ex99_1.htm)) |
| 2H 2027 | [Lexeo Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/lxeo/catalysts) | LXEO |  | scheduled | "Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000119312526345722/lxeo-ex99_1.htm)) |
| 2H 2027 | [Lexeo Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/lxeo/catalysts) | LXEO |  | scheduled | "Based on the study size and duration of SUNRISE-FA 2, as well as expected PPQ and process validation requirements, Lexeo expects a topline data readout in the second half of 2027 and a BLA submission under the accelerated approval pathway in the first half of 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000119312526270275/lxeo-ex99_1.htm)) |
| 2H 2027 | [LX3030 topline data readout](https://sec-api.dev/pdufa/lx3030) | LXEO |  | scheduled | "SUNRISE-FA 2 pivotal study continues enrollment and remains the company's top priority development program;topline data on track for 2H 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000119312526397221/lxeo-ex99_1.htm)) |

## Drugs

- [Cardiomyopathy](https://sec-api.dev/pdufa/cardiomyopathy): fa cardiomyopathy, friedreich ataxia
- [HEK293](https://sec-api.dev/pdufa/hek293): 
- [LX1001](https://sec-api.dev/pdufa/lx1001): 
- [LX3030](https://sec-api.dev/pdufa/lx3030): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/lxeo/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "LXEO catalysts: Lexeo Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/lxeo/catalysts

```bibtex
@misc{secapidev_companies_lxeo_catalysts_20261116,
  title        = {LXEO catalysts: Lexeo Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/lxeo/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_lxeo_catalysts_20261116","title":"LXEO catalysts: Lexeo Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/lxeo/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
